tradingkey.logo
tradingkey.logo
Suchen

Glaukos Corp

GKOS
Zur Watchlist hinzufügen
144.420USD
0.0000.00%
Handelsschluss 06/26, 16:00ETKurse um 15 Minuten verzögert
8.43BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Glaukos Corp Unternehmen

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Glaukos Corp Informationen

BörsenkürzelGKOS
Name des UnternehmensGlaukos Corp
IPO-datumJun 25, 2015
CEOBurns (Thomas William)
Anzahl der mitarbeiter995
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse1 Glaukos Way
StadtALISO VIEJO
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl92656
Telefon19493679600
Websitehttps://www.glaukos.com
BörsenkürzelGKOS
IPO-datumJun 25, 2015
CEOBurns (Thomas William)

Führungskräfte von Glaukos Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
49.04K
-3.13%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
+4.98%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
49.04K
-3.13%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Glaukos Corp?

Die fünf größten Anteilseigner von Glaukos Corp sind: Mr. Thomas William Burns

Wie viele Institutionen halten Anteile an Glaukos Corp (GKOS)?

Mit Stand vom 2026Q1 halten 702 Institutionen Anteile an Glaukos Corp, mit einem Gesamtmarktwert von etwa 59.35M, was 101.04% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -2784097.00 gestiegen.

Was ist die größte Einnahmequelle von Glaukos Corp?

Am 2026Q1 erzielte das Geschäft mit Glaucoma für Glaukos Corp den höchsten Umsatz in Höhe von 421.07M, was 82.98% des Gesamtumsatzes entspricht.
KeyAI